The role of cytokines in cancer cachexia

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 4, 2009, Pages 263-268

  Argilés, Josep M ^a   Busquets, Sílvia ^a   Toledo, Miriam ^a   López Soriano, Francisco J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

IL 1; IL 6; Myostatin; PIF; TNF ; Transcriptional factors; TWEAK

Indexed keywords

CYTOKINE; TRANSCRIPTION FACTOR;

ARTICLE; CACHEXIA; HUMAN; INFLAMMATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CACHEXIA; CYTOKINES; HUMANS; INFLAMMATION; METABOLISM; NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 74549129085     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283311d09     Document Type: Article

References (66)

1. Warren S. The immediate cause of death in cancer. Am J Med Sci 1932; 184:610-615.
2. Costelli P, Baccino FM. Cancer cachexia: from experimental models to patient management. Curr Opin Clin Nutr Metab Care 2000; 3:177-181.
3. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799. The definition of cachexia has been defined: 'cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass'. The prominent clinical feature of cachexia is weight loss in adults (corrected for fluid retention) or growth failure in children (excluding endocrine disorders). Anorexia, inflammation, insulin resistance and increased muscle protein breakdown are frequently associated with cachexia. Cachexia is distinct from starvation, age-related loss of muscle mass, primary depression, malabsorption and hyperthyroidism and is associated with increased morbidity.
4. Fearon KC, Moses AG. Cancer cachexia. Int J Cardiol 2002; 85:73-81.
5. Mantovani G, Anker S, Inui A, et al., editors. Cachexia and wasting: a modern approach. Berlin: Springer; 2006.
6. Lopez-Soriano J, Carbo N, Tessitore L, et al. Leptin and tumor growth in rats. Int J Cancer 1999; 81:726-729.
7. Sato T, Meguid MM, Miyata G, et al. Does leptin really influence cancer anorexia? Nutrition 2002; 18:82-83.
8. Kowalczuk A, Wiecek A, Franek E, Kokot F. Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy. Pol Arch Med Wewn 2001; 106:657-668.
9. Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med 2000; 5:421-426.
10. Brown DR, Berkowitz DE, Breslow MJ. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab 2001; 86:162-166.
11. Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 2002; 19:21-26.
12. Mantovani G, Maccio A, Madeddu C, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med 2001; 79:406- 414.
13. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78:554-561.
14. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000; 16:1009-1012.
15. Chance WT, Balasubramaniam A, Dayal R, et al. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994; 54:1869-1874.
16. King PJ, Widdowson PS, Doods H, Williams G. Effect of cytokines on hypothalamic neuropeptide Y release in vitro. Peptides 2000; 21:143-146.
17. Laviano A, Russo M, Freda F, Rossi-Fanelli F. Neurochemical mechanisms for cancer anorexia. Nutrition 2002; 18:100-105.
18. Bing C, Taylor S, Tisdale MJ, Williams G. Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 2001; 79:1004-1012.
19. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma 2009; 56:56-62. The authors suggested that elevated TNF-a serum level may have clinical significance in the development of cachexia in pancreatic adenocarcinoma patients.
20. Strassmann G, Fong M, Freter CE, et al. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 1993; 92:2152-2159.
21. Barton BE, Cullison J, Jackson J, Murphy T. A model that reproduces syndromes associated with human multiple myeloma in nonirradiated SCID mice. Proc Soc Exp Biol Med 2000; 223:190-197.
22. Barton BE, Murphy TF. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine 2001; 16:251-257.
23. Negri DR, Mezzanzanica D, Sacco S, et al. Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine 2001; 15:27-38.
24. Bosutti A, Grassi G, Fiotti N, et al. Decreased IL-10 mRNA expression in patients with advanced renal failure undergoing conservative treatment. Cytokine 2007; 40:71-74.
25. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008; 46:359-364. Cachexia in gastroesophageal cancers is associated with changes in acute-phase response proteins (APRP) concentrations. This, together with a direct relationship of APRPs with accelerated angiogenesis, may constitute a foundation for the association of APRPs and Glasgow Prognostic Score (GPS) with outcome in these malignancies.
26. Marzetti E, Carter CS, Wohlgemuth SE, et al. Changes in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restriction. Mech Ageing Dev 2009; 130:272-280. The authors indicated that aging is associated with decreased IL-15 signaling in rat gastrocnemius muscle, which may contribute to sarcopenia partly through enhanced TNF-α-mediated apoptosis. Preservation of IL-15 signaling by calorie restriction (CR, 40% calorie intake reduction) may therefore represent a further mechanism contributing to the antiaging effect of this dietary intervention in skeletal muscle.
27. Zhang D, Zhou Y, Wu L, et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann Clin Lab Sci 2008; 38:113-119. The results of this study indicated that the IL-6-634G allele is associated with increased susceptibility to cachexia and decreased survival time of Chinese patients suffering from pancreatic cancer.
28. Zhang L, Du J, Hu Z, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009; 20:604- 612. The results of this study suggested an interorgan response to high levels of AngII: hepatic production of IL-6 and SAA increases, and these mediators act synergistically to impair insulin/IGF-1 signaling, which promotes muscle proteolysis. Targeting the high levels of IL-6 and SAA in catabolic disorders might be a therapeutic approach to prevent muscle wasting.
29. Matthys P, Heremans H, Opdenakker G, Billiau A. Antiinterferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumourassociated cachexia. Eur J Cancer 1991; 27:182-187.
30. Henderson JT, Mullen BJ, Roder JC. Physiological effects of CNTF-induced wasting. Cytokine 1996; 8:784-793.
31. Wang MC, Forsberg NE. Effects of ciliary neurotrophic factor (CNTF) on protein turnover in cultured muscle cells. Cytokine 2000; 12:41-48.
32. Argilé s JM, Busquets S, Ló pez-Soriano FJ. The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun 2002; 293:1145- 1152.
33. Busquets S, Sanchis D, Alvarez B, et al. In the rat, tumor necrosis factor alpha administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis? FEBS Lett 1998; 440:348-350.
34. Busquets S, Aranda X, Ribas-Carbo M, et al. Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine 2003; 22:1-4.
35. Ravasco P, Monteiro-Grillo I, Camilo M. How relevant are cytokines in colorectal cancer wasting? Cancer J 2007; 13:392-398.
36. Argiles JM, Lopez-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998; 1:245-251.
37. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1518-1523.
38. Baracos VE. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition 2000; 16:1015-1018.
39. Alvarez B, Quinn LS, Busquets S, et al. Tumor necrosis factor-alpha exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochim Biophys Acta 2002; 1542:66-72.
40. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002; 85:161-171.
41. van Royen M, Carbo N, Busquets S, et al. DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun 2000; 270:533-537.
42. Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 2001; 84:1135-1140.
43. Busquets S, Deans C, Figueras M, et al. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr 2007; 26: 614-618.
44. Carbo N, Busquets S, van Royen M, et al. TNF-alpha is involved in activating DNA fragmentation in skeletal muscle. Br J Cancer 2002; 86:1012-1016.
45. Moresi V, Garcia-Alvarez G, Pristera A, et al. Modulation of caspase activity regulates skeletal muscle regeneration and function in response to vasopressin and tumor necrosis factor. PLoS One 2009; 4:e5570. The results showed that AVP counteracts the effects of TNF through cross-talk at the Hsp70 level. Therefore, muscle regeneration, both in the absence and in the presence of cytokines, may be enhanced by increasing Hsp70 expression.
46. Alter J, Rozentzweig D, Bengal E. Inhibition of myoblast differentiation by tumor necrosis factor alpha is mediated by c-Jun N-terminal kinase 1 and leukemia inhibitory factor. J Biol Chem 2008; 283:23224-23234. The authors described that TNF-α promotes myoblast proliferation through JNK1 and prevents myoblast differentiation through JNK1-mediated secretion of LIF.
47. Li H, Mittal A, Paul PK, et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J Biol Chem 2009; 284:4439-4450. The study unveils a novel mechanism of skeletal muscle tissue destruction in pathological conditions.
48. Dogra C, Changotra H, Wedhas N, et al. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007; 21:1857-1869.
49. Penner CG, Gang G, Wray C, et al. The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun 2001; 281:1331-1336.
50. Costelli P, Muscaritoli M, Bossola M, et al. Skeletal muscle wasting in tumorbearing rats is associated with MyoD down-regulation. Int J Oncol 2005; 26:1663-1668.
51. Busquets S, Carbo N, Almendro V, et al. Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 2001; 167:33-38.
52. Moore-Carrasco R, Busquets S, Almendro V, et al. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol 2007; 30:1239-1245.
53. Fernandez-Celemin L, Pasko N, Blomart V, Thissen JP. Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 2002; 283:E1279-1290.
54. Li YP, Schwartz RJ, Waddell ID, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998; 12:871-880.
55. Brenner DA, O'Hara M, Angel P, et al. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 1989; 337: 661-663.
56. Thinakaran G, Ojala J, Bag J. Expression of c-jun/AP-1 during myogenic differentiation in mouse C2C12 myoblasts. FEBS Lett 1993; 319:271-276.
57. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89:381-410. Very interesting review about the molecular mechanisms of cancer cachexia.
58. Penner G, Gang G, Sun X, et al. C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. Am J Physiol Regul Integr Comp Physiol 2002; 282:R439-444. (Pubitemid 34664594)
59. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
60. Coletti D, Yang E, Marazzi G, Sassoon D. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 2002; 21:631-642.
61. Puigserver P, Rhee J, Lin J, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 2001; 8:971-982.
62. Costelli P, Muscaritoli M, Bonetto A, et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008; 38:531- 538. The authors suggested that myostatin pathway should be regarded as a potential therapeutic target in cancer cachexia.
63. Liu CM, Yang Z, Liu CW, et al. Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 2008; 15:155-160. The study demonstrated the feasibility using antisense strategy with myostatin antisense RNA for the treatment of muscle-wasting conditions.
64. Cahlin C, Korner A, Axelsson H, et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000; 60:5488-5493.
65. Wiedenmann B, Malfertheiner P, Friess H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008; 6:18-25. The authors concluded that adding infliximab to gemcitabine to treat cachexia in advanced pancreatic cancer patients was not associated with statistically significant differences in safety or efficacy when compared with placebo.
66. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.Gut 2005; 54:540-545.